Publication date: Available online 26 August 2020Source: BrachytherapyAuthor(s): Yao Jiang, Guiling Li, Biyuan Xing, Ye Wang, Zhao Liu, Yingchao Zhao
Mark above section as read
Publication date: Available online 26 August 2020Source: Clinical TherapeuticsAuthor(s): Y.B. Wang, Z.Y. Yang, W.P. Zhang
Mark above section as read
Summary Two novel chemotherapeutic chalcones were synthesized and their structures were confirmed by different spectral tools. Theoretical studies such as molecular modeling were done to detect the mechanism of action of these compounds. In vitro cytotoxicity showed a strong effect against all tested cell lines (MCF7, A459, HepG2, and HCT116), and low toxic effect against normal human melanocytes (HFB4). The lung carcinoma cell line was chosen for further molecular studies. Real-time...
Summary Purpose The CKD4/6 inhibitor abemaciclib is related to adverse events such as hematological toxicity and increase in serum creatinine levels associated with abemaciclib pharmacokinetics. Increase in serum creatinine levels is considered a result of competition with abemaciclib via organic cation transporter 2 and multidrug and toxic compound extrusion. Therefore, we evaluated the association among serum creatinine levels, serum abemaciclib concentrations, and adverse events...
Mark above section as read
Publication date: September 2020Source: Photodiagnosis and Photodynamic Therapy, Volume 31Author(s): Jonathan Hong-Man Sin, Stephen Hamlet, Laurence J. Walsh, Robert M. Love, Roy George
Publication date: September 2020Source: Photodiagnosis and Photodynamic Therapy, Volume 31Author(s): Sogol Saberi, Mahboubeh Rouzsaz, Farhad Shafie, Sadra Einizadeh, Mohammad Javad Kharazifard, Sima Shahabi
Mark above section as read
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου